VRK3 Antibody (C-8): sc-398771

VRK3 Antibody (C-8) is a mouse monoclonal IgM antibody that detects VRK3 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-VRK3 antibody (C-8) is available as the non-conjugated form. The vaccinia-related kinase 3 (VRK3) is a crucial nuclear protein composed of 474 amino acids and belongs to the serine/threonine protein kinase family, characterized by a single protein kinase domain. VRK3 plays a significant role in cellular signaling pathways, particularly in regulating the activity of extracellular signal-regulated kinases (ERKs). By directly binding to mitogen-activated protein kinase phosphatases, specifically the vaccinia H1-related phosphatase, VRK3 facilitates the dephosphorylation and inactivation of ERK within the nucleus, thereby influencing various transcriptional processes. The gene encoding VRK3 is located on human chromosome 19, which contains over 63 million bases and more than 1,400 genes, representing over 2% of the human genome. The widespread expression of VRK3 across human tissues underscores its importance in cellular functions and potential implications in various diseases, making VRK3 (C-8) antibody an essential tool for researchers studying kinase signaling pathways and their effects on cellular behavior.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VRK3 Antibody (C-8) References:

1. Expression of the VRK (vaccinia-related kinase) gene family of p53 regulators in murine hematopoietic development.  |  Vega, FM., et al. 2003. FEBS Lett. 544: 176-80. PMID: 12782311
2. Characterization of three paralogous members of the Mammalian vaccinia related kinase family.  |  Nichols, RJ. and Traktman, P. 2004. J Biol Chem. 279: 7934-46. PMID: 14645249
3. The vaccinia-related kinases phosphorylate the N' terminus of BAF, regulating its interaction with DNA and its retention in the nucleus.  |  Nichols, RJ., et al. 2006. Mol Biol Cell. 17: 2451-64. PMID: 16495336
4. The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines.  |  Blanco, S., et al. 2006. FEBS J. 273: 2487-504. PMID: 16704422
5. Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase.  |  Kang, TH. and Kim, KT. 2006. Nat Cell Biol. 8: 863-9. PMID: 16845380
6. VRK3-mediated inactivation of ERK signaling in adult and embryonic rodent tissues.  |  Kang, TH. and Kim, KT. 2008. Biochim Biophys Acta. 1783: 49-58. PMID: 18035061
7. Cisplatin-mediated activation of extracellular signal-regulated kinases 1/2 (ERK1/2) by inhibition of ERK1/2 phosphatases.  |  Gozdz, A., et al. 2008. J Neurochem. 106: 2056-67. PMID: 18665890
8. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site.  |  Scheeff, ED., et al. 2009. Structure. 17: 128-38. PMID: 19141289
9. Presumed pseudokinase VRK3 functions as a BAF kinase.  |  Park, CH., et al. 2015. Biochim Biophys Acta. 1853: 1738-48. PMID: 25899223
10. VRK3-mediated nuclear localization of HSP70 prevents glutamate excitotoxicity-induced apoptosis and Aβ accumulation via enhancement of ERK phosphatase VHR activity.  |  Song, H., et al. 2016. Sci Rep. 6: 38452. PMID: 27941812
11. VRK3 depletion induces cell cycle arrest and metabolic reprogramming of pontine diffuse midline glioma - H3K27 altered cells.  |  Menez, V., et al. 2023. Front Oncol. 13: 1229312. PMID: 37886173
12. Identification of two novel human putative serine/threonine kinases, VRK1 and VRK2, with structural similarity to vaccinia virus B1R kinase.  |  Nezu, J., et al. 1997. Genomics. 45: 327-31. PMID: 9344656

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VRK3 Antibody (C-8) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-VRK3 Antibody (C-8) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VRK3 Antibody (C-8) Specifications

Alternate Product Name: VRK3

Product Clone Name: C-8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM kappa light chain

Amino Acids: 341-364

Epitope Target: VRK3

Epitope Species: human

Product Reactivity/Detection: All VRK3 isoforms 1 and 2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for VRK3 Antibody (C-8): P: Blocking Peptide